PubMed Health⌕ Search

Biomedical subjects

J R Ogez

Publications and source records attributed to J R Ogez.

11 recordsLinked to original sources
PubMed1996

Vascular endothelial growth factor augments muscle blood flow and function in a rabbit model of chronic hindlimb ischemia.

Animal studies have shown that angiogenic factors can increase vascularity and improve blood pressure (BP) in an ischemic limb. Whether changes in these parameters are indicators of significant improvement in muscle function has not been demonstrated. In a rabbit model of hind limb ischemia, we measured blood flow in the extensor digitorum longus muscle (EDL) both at rest and during electrical stimulation. Ablation of the femoral artery caused significant reductions in resting and stimulated EDL blood flow. The chronic reduction in perfusion caused impairment of muscle function (p < 0.01). At 28 days after a single administration of vascular endothelial growth factor (VEGF), stimulated muscle blood flow (3 mg/kg intravenously, i.v.) and muscle function [1 mg intrarterially (i.a.) or 3 mg/kg i.v.] were significantly improved as compared with that of vehicle-treated controls. Simultaneous measurement of the hemodynamic responses in the contralateral limb and in the kidneys confirmed that the effects of VEGF were confined to the ischemic limb. The data agree with findings that angiogenic factors increase perfusion through angiogenesis. We hypothesized that neovascularization allows work-associated muscle hyperemia, resulting in a significant improvement in muscle function. Similar clinical improvements in muscle function would signify a substantial advance in the treatment of peripheral vascular disease.

Angiogenesis Inducing Agents↗
PubMed1995

Use of multifactorial analysis to develop aqueous two-phase systems for isolation of non-native IGF-I.

A high yield procedure was developed to solubilize and extract IGF-I from recombinant E. coli by adding chaotrope and disulfide reductant to alkaline fermentation broth. To enhance centrifugation performance and recovery yield, a salt/polymer aqueous two-phase extraction procedure was developed whereby soluble non-native IGF-I and biomass solids are enriched in separate liquid phases. To develop this extraction system a multifactorial experimental approach was used to simultaneously map the phase diagram and identify conditions to suitably partition IGF-I and cell remnants. The presence of urea in these systems tended to disrupt two-phase formation and solids sedimentation. This, in turn, constrained the concentrations of phase forming solutes which could be effectively used. Systems containing low levels of salt (less than about 4% w/w) and polymer (less than about 10% w/w) did not form two phases. Systems containing high levels of salt (greater than about 7% w/w) and polymer (greater than about 18% w/w) formed two phases with floating solids. Intermediate levels of salt (between about 4% and 7% w/w) and polymer (between about 10% and 18% w/w) formed two phases in which solids were enriched in the heavy phase. Systems in this latter desired category were produced with a variety of different salts and polymers and all enriched non-native IGF-I in the light phase. Highest recovery yield (about 90%) was obtained with systems composed of 5% sodium sulfate and 14% PEG-8000.(ABSTRACT TRUNCATED AT 250 WORDS)

Centrifugation↗
PubMed1994

Large scale, in situ isolation of periplasmic IGF-I from E. coli.

Human insulin-like growth factor I (IGF-I) accumulates in both folded and aggregated forms in the fermentation medium and cellular periplasmic space when expressed in E. coli with an endogenous secretory signal sequence. Due to its heterogeneity in form and location, low yield of IGF-I was obtained using a typical refractile body recovery strategy. To enhance recovery yield, a new procedure was developed to solubilize and extract IGF-I from cells while in fermentation broth. This method, called in situ solubilization, involves addition of chaotrope and reductant to alkaline fermentation broth and provides recovery of about 90% of all IGF-I in an isolated supernatant. To further enhance recovery, a new aqueous two-phase extraction procedure was developed which partitions soluble non-native IGF-I and biomass solids into separate liquid phases. This two-phase extraction procedure involves addition of polymer and salt to the solubilization mixture and provides about 90% recovery of solubilized IGF-I in the light phase. The performance of the solubilization and aqueous extraction procedures is reproducible at scales ranging from 10 to 1000 liters and provides a 70% cumulative recovery yield of IGF-I in the isolated light phase. The procedure provides significant initial IGF-I purification since most host proteins remain cell associated during solubilization and are enriched in heavy phase. ELISA analysis for E. coli proteins indicates that 97% of the protein in the light phase is IGF-I. Together, the techniques of in situ solubilization and aqueous two-phase extraction provide a new, high yield approach for isolating recombinant protein which is accumulated in more than one form during fermentation.

Escherichia coli↗
PubMed1994

Effect of environment on insulin-like growth factor I refolding selectivity.

Recombinant human insulin-like growth factor I (IGF-I), a 70-amino-acid peptide containing three disulphide bonds, produces two monomeric and several multimeric species during refolding. To optimize production of correctly folded IGF-I, conditions which influence protein refolding, stability and solubility were systematically examined. Combinations of solution components and conditions were analysed to identify synergistic interactions which enhance or reduce refolding efficiency. IGF-I concentration had the largest effect on formation of correctly folded peptide, due to competing association reactions. Solution polarity had the next largest individual effect, both on the level of multimeric peptide and on the relative proportion of correctly folded to misfolded monomeric peptide. Salt type and concentration and chaotrope type and concentration also had large individual effects on the distribution of IGF-I forms produced. Solution polarity modulated the effects of many other conditions including chaotrope concentration, salt type and concentration, and osmolyte concentration. Simultaneously decreasing the solution polarity and increasing the salt concentration improved the yield of correctly folded IGF-I relative to either individual change. Optimum solution conditions for refolding were 2M urea, 1M NaCl and 20% (v/v) ethanol. A possible mechanism for the importance of solution polarity on IGF-I refolding is discussed.

Amino Acid Sequence↗
PubMed1990

Downstream processing of proteins from mammalian cells.

Less than a decade ago, the use of continuous mammalian cell lines for the production of cloned proteins was considered strictly a research tool. At that time, few thought it possible to allay the many safety concerns associated with transformed cells. It soon became clear that mammalian expression systems had numerous advantages over bacteria for production of therapeutic proteins, initiating a multidisciplinary effort to address these concerns in a thorough and reliable manner. The success of these efforts is exemplified by the emergence of product molecules into the market. Today, there are seven recombinant human therapeutics that have received FDA approval. Almost half of them (OKT3, t-PA, and EPO) are produced in mammalian cells, with the remainder produced in bacteria (insulin, growth hormone, and alpha-interferon) or yeast (hepatitis vaccine). At least a dozen more recombinant cell culture products are in advanced human clinical trials. With the accumulation of data and experience, continuous mammalian cell lines will no doubt be the preferred hosts for many future products of biotechnology.

Animals↗
PubMed1989

Downstream processing of proteins: recent advances.

This review on the downstream processing of proteins describes innovations that have occurred in the field since 1983. Several areas have seen particularly high levels of achievement, and are accorded expanded coverage relative to our previous review [1]. As an example, the increasing integration of downstream operations with upstream technologies, such as molecular biology and fermentation, has led to the development of some very powerful processes. The degree to which organizations understand that there needs to be one unified process, rather than the independent steps of cloning, fermentation and recovery, seems directly related to the ultimate speed and success of the development effort. In 1983 one of the most active development areas was chromatography, especially affinity chromatography. This is still true today, and this topic has been expanded to include biospecific adsorptions that would not traditionally be classified as chromatography. With more proteins being developed for human administration, there has been an increased emphasis on all aspects of process hygiene. In addition, there has been much discussion about the impact of regulatory demands on the design and development of the manufacturing processes. Therefore, a section has been added which covers several of the regulatory issues that have been raised for products of the new biotechnology. Finally, as some of the early process development achievements are now beginning to bear fruit in the form of patents, we have increased our citation of this area of the literature.

Journal Article↗
PubMed1987

The properties of recombinant chicken growth hormone and its effects on growth, body composition, feed efficiency, and other factors in broiler chickens.

Recombinant chicken GH (rcGH) was produced and characterized. Comparison of protein sequence, amino acid composition, mol wt, purity, and immunocross-reactivity showed that except for the N-terminal methionyl group arising from the bacterial expression system, the recombinant and pituitary-derived cGHs were identical. When tested in a hypophysectomized rat growth assay, the recombinant and pituitary materials had the same specific bioactivity. Within 60 min after sc injection of rcGH (480-960 micrograms/kg) in chickens, plasma GH levels increased 4- to 6-fold and remained significantly elevated for at least 5 h. Thrice-daily injections from age 2-24 days had little effect on growth or feed consumption in either male or female broiler chicks. Plasma levels of insulin and triglycerides were significantly elevated by rcGH in 24-day-old females, but not in males. Injection of rcGH counteracted a reduction of tibia length observed in saline-injected controls. The rcGH had no effect on carcass protein, ash content, or nitrogen retention. It is important to note that exogenous GH can be a productivity-enhancing factor in other commercially important species. Administration of bovine GH to cows has been shown to induce a significant increase in milk production (28). This study shows that administration of rcGH to chickens can lead to some significant metabolic effects. However, it is the conclusion of this report that the level of circulating GH is not the limiting factor in the growth of this highly selected species.

Amino Acid Sequence↗
PubMed1983

Downstream processing of proteins.

This review focuses on the recovery of proteins from fermented starting materials, covering developments that have appeared in the literature since 1979. The major subjects discussed include cell disruption and extraction, solid/liquid separations, chromatography, separations in solution, and finishing operations. While advances have occurred in every area, the greatest diversity of innovation has taken place in the fields of chromatography and tangential-flow filtration.

Journal Article↗
PubMed1977

A novel chemical modification of delta 5-3-ketosteroid isomerase occurring during its 3-oxo-4-estren-17 beta-yl acetate-dependent photoinactivation.

The chemical change responsible for the 3-oxo-4-estren-17 beta-yl acetate-dependent photoinactivation of delta 5-3-ketosteroid isomerase has been identified by amino acid analysis and amino acid sequencing. Amino acid analysis of the enzyme and its photoinactivated derivative shows that photoinactivation is accompanied by loss of nearly 1 residue of aspartic acid/polypeptide chain and an increase in nearly 1 residue of alanine. Edman degradation of a peptide comprising residues 31 to 48 from native isomerase showed the presence of aspartic acid at residue 38. When the corresponding peptide from photoinactivated enzyme was sequenced, residue 38 was revealed to be alanine.

Alanine↗
PubMed1976

Interaction of cyclic adenosine 3':5'-monophosphate with protein kinase. Equilibrium binding models.

A number of potential models for the interaction of cyclic AMP with protein kinase (RC or R2C2) have been examined. These include: Model 1, the simultaneous binding of cyclic AMP and release of C (catalytic subunit) from an independent RC protomer; Model 2, dissociation of an independent RC protomer prior to cyclic AMP binding to R (regulatory subunit); Model 3, cyclic AMP binding to RC prior to the dissociation of C; Model 4, random binding of cyclic AMP and dissociation of C with an interaction factor alpha less than 1; Model 5, release of 2C concomitant with the binding of one cyclic AMP to R2C2 followed by binding of the second cyclic AMP to the vacant R subunit; and Model 6, the simultaneous binding of cyclic AMP and release of C from one RC protomer resulting in a greater "affinity" of the other RC protomer for cyclic AMP, i.e., a cooperative version of Model 1. All the above models yield [cyclic AMP]0.5 values that increase with increasing protein concentration and Hill plots with average slopes equal to or less than 1.0 in the usual experimental range (10 to 90% of saturation). The Hill plots can be nonlinear, but for each model the exact shape of the plot changes in a characteristic (diagnostic) manner with changing protein concentration. Skeletal muscle protein kinase yields relatively linear Hill plots with napp values greater than 1.0. Consequently, Models 1 to 6 are not likely candidates. However, Model 2 is an excellent alternative model for proteins that display "negative cooperativity" with respect to the binding of a ligand. The properties of several "linear", "tetrahedral", and "all-or-nothing" cooperative models have also been examined. These include Models 7, A, B, and C and 8, A, B, and C which are cooperative versions of Models 2 and 3, respectively, and Model 9, a cooperative version of random Model 4. Model 9 is the most general model from which all others can be derived. Models 9 and 7, A, B, and C in which the prior dissociation of C greatly enhances or is an absolute requirement for cyclic AMP binding to R, are likely candidates for skeletal muscle protein kinase. All four of these models are capable of yielding Hill plots with average slopes greater than 1, and napp values that decrease with increasing protein concentration (in agreement with published data). In addition, in all four models the tight binding of MgATP to R2C2 yields decreased napp values and increased [cyclic AMP]0.5 values (also consistent with published data).

Binding Sites↗